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Results: At 60 min, 850/2192 pts with AS >3 had an 11% greater absolute frequency of
complete STR (>70%) than 344/1239 with low AS (<3) p <0.001. Patients surviving to
discharge (fig.), showed that within each subgroup of STR, patients with high AS were
statistically more likely to have a small QRS infarct at discharge as compared to those
with low AS p<0.001. Moreover in a multivariate logistic regression model including base-
line characteristics, Σ ST, STR, time to treatment, the AS >3proved the strongest predic-
tor of small infarct size (OR=0.374, CI= 0.315-0.445).
Conclusion: Even after adjusting for time to treatment the AS provides novel insight into
the likelihood of STR 60 min after fibrinolysis and the probability of a smaller infarct size
regardless of the extent of STR. 
1117-90 Establishing a New Therapeutic Activated Partial 
Thromboplastin Time Range for Unfractionated Heparin 
for Acute Coronary Syndromes
Michael S. Lee, Venu Menon, Joseph Schappert, James R. Wilentz, Varinder Singh, 
Judith Hochman, St. Luke's-Roosevelt Hospital Center, New York City, NY
Introduction: The therapeutic aPTT range of 50 to 70 sec recommended by the ACC/
AHA for patients receiving unfractionated heparin (UFH) for acute coronary syndromes
(ACS) is vulnerable to variation in test reagents. Rather than use the standard therapeu-
tic aPTT range, it has been recommended that each institution establish its own thera-
peutic aPTT range based upon anti-factor Xa levels. We evaluated our institution's
therapeutic aPTT range by examining the correlation between aPTTs and anti-factor Xa
levels and established a new therapeutic aPTT range with a new thromboplastin reagent
based upon the therapeutic anti-factor Xa levels.
Methods: 62 plasma samples were collected from 26 consecutive patients receiving
UFH for ACS. APTTs measured with a thromboplastin reagent and a new thromboplastin
reagent and anti-factor Xa levels were obtained on each plasma sample. Linear regres-
sion analysis was performed to establish a new therapeutic aPTT range from corre-
sponding therapeutic anti-factor Xa levels.
Results: 32% of patients with target range aPTTs had anti-factor Xa levels below the
accepted level of 0.35-0.7 U/mL for ACS while 68% had therapeutic anti-factor Xa levels.
When the same blood was tested with a new thromboplastin reagent, only 9% of patients
with target range aPTTs had anti-factor Xa levels <0.35 U/mL while 91% had therapeutic
anti-factor Xa levels. The Pearson correlation coefficient (r) for the new thromboplastin
reagent was 0.93. The slope of the regression line was 221.3. The therapeutic aPTT
range established with the new thromboplastin reagent was 61-100 sec.
Conclusion: Monitoring aPTTs without standardizing the thromboplastin reagent may
not adequately reflect therapeutic heparin levels. Despite apparently therapeutic aPTTs,
patients treated with UFH may be under-anticoagulated. Our new anti-Xa-adjusted thera-
peutic aPTT range shows an increase in the positive predictive value of aPTTs. Large-
scale clinical studies are needed to determine the optimal anti-factor Xa range for ACS
patients treated with UFH, with further refinements if GP IIb/IIIa antagonists are concom-
itantly used and to show a clinical benefit for monitoring heparin levels with anti-factor Xa
levels.
1117-91 Invasive Therapy Along With Glycoprotein IIb/IIIa 
Inhibitors and Intracoronary Stents Improves Survival in 
Non-ST-Segment Elevation Acute Coronary Syndromes
Anthony A. Bavry, Dharam J. Kumbhani, Rene Quiroz, Suneil R. Ramchandani, Satish 
Kenchaiah, Harvard School of Public Health, Boston, MA, Cleveland Clinic Foundation, 
Cleveland, OH
Background: Although several clinical trials have shown that early invasive therapy in UA/
NSTEMI patients reduces the risk of composite endpoints inclusive of death, MI or
angina, it is unclear whether such an approach improves survival.
Methods: We conducted a meta-analysis on five studies in a total of 6,766 UA/NSTEMI
patients who were randomized to either routine invasive (n=3,371) versus conservative
therapy (n=3,395) in the era of GP IIb/IIIa inhibitors and intra-coronary stents.
Results: As compared with conservative therapy, an invasive approach was associated
with a reduction in the risk of all-cause mortality at 6-12 months (3.3% vs. 4.2%, relative
risk [RR] 0.80, 95% confidence interval [CI] 0.63 to 1.03) and at 24 months (5.0% vs.
6.5%, RR 0.77, 95% CI 0.60 to 0.99) of follow-up. Although invasive therapy reduced the
risk of the composite endpoint of death or MI at 6-12 months in men (RR 0.68, 95% CI
0.57 to 0.81) and troponin positive patients (RR 0.74, 95% CI 0.59 to 0.94), the results for
women (RR=1.07, 0.82 to 1.41) and troponin negative patients (RR=0.82, 0.59 to 1.14)
were equivocal. 
Conclusions: Invasive therapy in UA/NSTEMI patients with adjunctive use of GP IIb/IIIa
inhibitors and intra-coronary stents improves survival. Enhanced risk stratification is
needed in women and troponin negative patients so that invasive therapy may be more
effectively recommended in these groups. 
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1118-77 Effects of Carvedilol Compared to Atenolol on Ejection 
Fraction and Clinical Endpoints After Myocardial 
Infarction
Gisli Jonsson, Michael Abdelnoor, Carl Müller, Sverre Erik Kjeldsen, Ingrid Os, Arne 
Westheim, Ullevaal University Hospital, Oslo, Norway
Background: Beta-blockers have been found to reduce mortality and morbidity in post-
myocardial infarction (MI) patients. However, it is not fully understood, whether all beta-
blockers have similiar favourable cardiovascular effects. The aim of this study was to
compare the effects of carvedilol and atenolol on global and regional ejection fraction
(EF), and on predefined cardiovascular endpoints.
Methods: In a randomized, prospective, open and endpoint-blinded single center study,
118 patients received carvedilol (mean dosage 36.2 + 15.1 mg) and 114 patients atenolol
(mean dosage 72.1 + 30.6 mg). No difference in baseline data, such as age, gender,
race, smoking, hypertension, dibetes mellitus or lipid lowering treatment, was observed.
There was no difference in baseline characteristics regarding infarct localization, reperfu-
sion therapy and acute treatment between the groups. Treatment with aspirin (96%), sta-
tin (98%), and ACE-inhibitors was equal in the 2 groups. The global and regional left
ventricular (LV) EF were evaluated with gated blood pool scintigraphy.
Results: In the carvedilol group 90 cardiovascular endpoints were observed compared
to 104 endpoints in the atenolol group, with a hazard ratio (RR) 0.84 with 95% confidence
interval (0.74-0.94) (p=0.002). This occured despite similar global LVEF was 55 + 11% at
baseline, 57 + 10% at 3 months and 57 + 10% at 12 months in the carvedilol group and
53 + 9%, 56 + 10% and 56 + 9% in the atenolol group respectively. No difference in
regional EF was observed in the two groups. The main contributor to the difference in
cardiovascular endpoints was a composite of cardiovascular deaths, non-fatal MI, and
congestive heart failure (worsening and hospitalization).
Conclusion: In patients following an acute MI, carvedilol treatment compared to atenolol
was associated with a significant reduction in combined cardiovascular endpoints despite
that no difference in global or regional ejection fractions was found. Thus other mecha-
nisms than remodelling might explain this difference in clinical effect between the two
drugs.
1118-78 Primary Angioplasty Versus Facilitated Intervention 
(Tenecteplase Plus Stenting) in Patients With ST 
Elevated Acute Myocardial Infarction: Final Results of 
the GRACIA-2 Trial
Francisco Fernandez-Aviles, Joaquin J Alonso, Alfonso Castro-Beiras, Javier Goicolea, 
Jesus Blanco, Juan Alonso, Juan Lopez-Mesa, Luis Diaz-Llera, Nicolas Vazquez, Rosa 
Hernandez, Armando Perez, Javier Moreu, The GRACIA-2 Investigators, ICICOR, 
Hospital Clinico Valladolid, Valladolid, Spain
Background: Combined reperfusion therapies widely applicable could benefit the still
high proportion of patients (pts) with ST-elevated acute myocardial infarction (STEAMI)
for whom primary PCI is not available due to logistic reasons.
Methods: We compared the evolution of 212 pts with STEAMI (<12 hs from onset) ran-
domised to 2 strategies: 1) primary PCI optimally performed (stenting of culprit artery
under protection of abcximab within 3 hs from onset); or 2) a combined (facilitated) strat-
egy: immediate thrombolysis (T) with tenecteplase (full bolus dose adjusted by weight)
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and intravenous enoxaparin (30 mg) followed by angiography within 3-12 hs of randomis-
ation and adequate revascularisation (culprit artery plus non-culprit severe diseased
arteries threatening functionally important areas) with stenting or surgery. When T failed
(TIMI flow grade 0 or 1) abciximab was given before stenting. Heparin was stopped in
both groups after PCI. The co-primary endpoints were: infarct size (CK-MB mass, cTnT
release), left ventricle 6-week angiographic evolution (volume, ejection fraction, wall
motion index) and myocardial reperfusion (normalization of ST at 3 and 6 hs). The inci-
dence of cardiac and non-cardiac events was also compared.
Results: There were no differences between primary PCI and facilitated strategies in
terms of infarct size (CK-MB mass: 4768±3734 vs 4602±3371 ug/Lxh, p= 0.76; cTnT:
275±211 vs 242±156 ug/Lxh, p=0.55), left ventricular ejection fraction at 6 weeks (56±13
vs 56±12%, p= 0.9); wall motion index at six weeks (-1.1±0.6 vs -1.2±0.4, p= 0.1) and
myocardial perfusion (normalization of ST at 3 hs: 47 vs 46%, p= 0.83). However, in facil-
itated pts the incidence of complete ST resolution at 6 hs was higher (43 vs 61%,
p=0.03), and the rate of cardiac events at six month tends to be lower (death, reinfarction
or revascularization: 14% vs 9%).
Conclusions: According to the results of the GRACIA-2 trial, the strategy of performing
facilitated intervention is as safe as optimal primary PCI for pts with STEAMI. Results
also suggest that both strategies have equivalent efficacy in restoring myocardial perfu-
sion, preserving left ventricular size and function and beneficing clinical outcome.
1118-79 Drag Reduction by Polymer Infusion: A New Mechanism 
to Enhance Microcirculatory Perfusion for the Treatment 
of Ischemia
John J. Pacella, Erxiong Lu, Joan Gretton, David Fischer, Marina V. Kameneva, 
Flordeliza S. Villanueva, University of Pittsburgh, Pittsburgh, PA
Background: In the setting of severe, flow-limiting coronary artery stenosis, we have
previously shown that drag-reducing polymers (DRPs), which are unique, blood-soluble
macromolecules, have therapeutic potential because they further lower microvascular
resistance and enhance perfusion, even after autoregulation is exhausted. In bench stud-
ies involving rigid tubes, DRPs reduce resistance by altering the hydrodynamic proper-
ties of blood flow. Whether changing blood rheology is their mechanism of action in vivo,
or whether it also involves vasodilation is unclear. To test the hypothesis that DRPs
decrease resistance and increase blood flow without causing vasodilation, we examined
the microcirculation of the cremaster muscle in rats using intravital microscopy. Methods:
Catheters were placed in the carotid artery for pressure measurement in 13 anesthetized
rats. A flow probe was placed around the abdominal aorta. The cremaster muscle was
exposed and mounted on a microscope. Red blood cell (RBC) velocity and vessel diame-
ters were measured in arterioles (A), venules (V), and capillaries (C) pre- and post- intra-
venous DRP (polyethylene oxide, 1PPM). Vascular resistance was calculated as mean
arterial pressure/aortic flow. In 5 controls, topical nipride was applied to the cremaster to
confirm measurable vasoactivity in our model. Results: Arteriolar diameter increased
18±4% (p<0.03) after topical nipride in controls. DRP increased aortic flow (7.4±1.0 vs.
5.0±0.6 mL/min, p<0.002) and decreased vascular resistance (14.2±1.7 vs. 23.5±2.7
mmHg-min/mL, p<0.01). There was no significant change in diameter at any microvascu-
lar level in association with this resistance reduction. DRP increased RBC velocity in the
A (13.0±0.8 vs. 11.4±0.6 mm/sec, p<0.04), V (10.3±0.4 vs. 8.5±0.6 mm/sec, p<0.003)
and C (149±34 vs. 103±31 µm/sec, p<0.02). Conclusions: DRPs lower vascular resis-
tance and increase flow without causing vasodilation. The rise in flow is accompanied by
an increase in microvascular RBC velocity. Primary enhancement of microvascular perfu-
sion through modulation of the rheological properties of blood represents a promising,
novel therapeutic strategy for ischemic syndromes.
1118-80 Effects of Intracoronary Low-Dose Enalaprilat on QT 
Dynamicity in Patients Undergoing Direct Percutaneous 
Coronary Intervention for Acute Myocardial Infarction
Hendrik Bonnemeier, Ulrich Schaefer, Thomas Kurz, Uwe Wiegand, Jasmin Ortak, Hugo 
A. Katus, Gert Richardt, University Luebeck, Medical Clinic II, Luebeck, Germany
Experimental data suggest that ACE inhibition results in an increased ventricular electri-
cal stability in acute myocardial infarction (AMI). As electrical stability is largely depen-
dent on ventricular repolarization, we sought to determine the impact of low-dose
intracoronary application of enalaprilat (EN) as an adjunct to direct PCI on the QT/RR
relationship in AMI.
Methods and Results: Twenty-two patients with AMI who underwent direct PCI (TIMI 3
flow) were randomized to EN (50µg) or saline (SA), given immediately after reperfusion.
On hospital admission a 24-hour-Holter-ECG was initiated. Slopes of the linear QT/RR
regression were determined for the time intervals before reperfusion and after reperfu-
sion. A total of 6 patients in the EN group and 6 patients in the SA group had valid Holter-
ECGs for QT analysis. Mean RR interval and QT interval were not significantly different
between the EN and the SA groups before and after PCI. There were also no significant
differences regarding QT/RR slopes between EN and SA groups before PCI. After PCI,
QT/RR slopes significantly decreased in the EN group, whereas there were no significant
alterations in the SA group.
Conclusion: Intracoronary EN therapy as an adjunct to direct PCI significantly
decreases QT/RR slopes, suggesting a normalization of the coupling between heart rate
and repolarization by improving electrical restitution. Thus, our findings offer new insights
into possible beneficial effects of ACE inhibition on electrical stability in AMI. 
1118-81 The Impact of Abciximab on Final Infarct Size and Left 
Ventricular Function of Patients With Acute Myocardial 
Infarction Undergoing Primary Stenting: Insights From 
the Abciximab and Carbostent Evaluation (ACE) Trial
Guido Parodi, Angela Migliorini, Roberto Sciagrà, Gentian Memisha, Renato Valenti, 
David Antoniucci, Careggi Hospital, Florence, Italy
OBJECTIVES: We sought to evaluate the impact of abciximab, as adjunctive therapy to
routine infarct-related artery (IRA) stenting, on effectiveness of myocardial reperfusion.
BACKGROUND: The impact of abciximab on left ventricular (LV) volumes and function of
patients with acute myocardial infarction (AMI) undergoing IRA stenting is not yet
defined. METHODS: Four hundreds unselected patients with AMI were randomised 1:1
to IRA stenting alone or stenting plus abciximab. One- month gated 99m-Tc Sestamibi
SPECT had to be performed in a pre-specified subgroup of 250 patients to evaluate inf-
arct size and LV volumes. RESULTS:Out of the 250 patients planned for the scintigraphic
assessment, 8 died within the first month, 12 dropped out of the study protocol, 13 were
excluded because gated acquisition was precluded by arrhythmias or technical reasons,
and 35 had a previous myocardial infarction preventing the index infarct size evaluation.
Thus, 182 patients represent the final study group (99 patients were randomized to abcix-
imab therapy and 83 to stenting alone). There were no differences in the baseline clinical
and angiographic characteristics, and in discharge therapy between the 2 groups. In the
abciximab group infarct size was smaller than in stenting alone group (14.3±11.7 versus
19.1±13.0 %; p=0.01), resulting in smaller LV end-diastolic volume index (57.8±20.0 ver-
sus 64.6±20.8 mL/m2; p=0.03), and LV end-systolic volume index (31.7±17.4 versus
37.5±18.6 mL/m2; p=0.03). One-month LV ejection fraction was significantly higher in
patients randomized to abciximab, as compared to stenting alone (47.4±11.3 versus
43.9±11.7 %; p=0.04). Reinfarction within 30 days occurred in 3 (4%) of patients of the
stenting alone group as compared to none of the abciximab group (p=0.056). After
excluding the 3 patients who experienced a reinfarction, the beneficial effect of abciximab
on LV volumes and function still persists. CONCLUSIONS: The use of abciximab, as a
standard adjunctive therapy to IRA, leads to the reduction in infarct size, resulting in
smaller 1-month LV volumes and better LV function. The effect is not explained by the
lower reinfarction rate.
1118-82 Distinct Modes of Cardiovascular Death Associated 
With Impaired Epicardial and Myocardial Perfusion 
Following Fibrinolysis for ST Elevation Myocardial 
Infarction
Stephen D. Wiviott, Marc S. Sabatine, David A. Morrow, Raphaelle Dumaine, Sabina A. 
Murphy, Kieth E. Boundy, Christopher P. Cannon, C. Michael Gibson, Brigham and 
Women's Hospital, Boston, MA
Background: Despite fibrinolysis for ST-elevation MI (STEMI), a significant mortality
remains. A comprehensive analysis of cause of death and angiographic features could
provide important information for therapeutic decision-making and understanding patho-
pysiology.
Methods: 3683 patients from an angiographic database STEMI fibrinolysis trials were
analyzed. 180 deaths (4.9%) were observed. Angiographic features were measured by a
blinded core lab.
Results: Causes of death included: CHF/Shock (22%), Stroke/ICH (18%), dysrhythmia
(16%), cardiac rupture (13%), MI (12%), other cardiac (7%), hemorrhage (3%). Those
with cardiac death compared to survivors were less likely to have TIMI flow grade (TFG)
2-3 (p<0.001) and TIMI Myocardial Perfusion Grade (TMPG) 2-3 (p=.004); had higher
Corrected Frame Counts (CTFC, 68 vs.52, p<0.001), and were more likely to have 3 ves-
sel CAD (p=0.001) or thrombus (p=0.001). Among cardiac deaths, TFG 0-1, higher
CTFC, were associated with CHF/Shock (figure); TFG 0-1 and TMPG 0-1 were associ-
ated with dysrhythmia (figure) and cardiac rupture (p<0.05). There were no angiographic
correlates of CVA/hemorrhage.
Conclusions: Impairment of epicardial and myocardial perfusion were associated with
cardiovascular mortality. Angiographic features differed among causes of death. These
angiographic correlates with mortality may aid in understanding the limitations of reperfu-
sion therapy and the search for new modalities to reduce mortality in STEMI. 
